QLGN News and Press, Qualigen Therapeutics Inc. From 04/15/21

Qualigen Therapeutics Inc. (NASDAQ:QLGN) traded today at a new 52-week low of $2.02. Approximately 1.3 million shares have changed hands today, as compared to an average 30-day volume of 892,000 shares. In the past 52 weeks, Qualigen Therapeutics Inc. share prices are bracketed by a curr...

Shares of Qualigen Therapeutics Inc. (NASDAQ:QLGN) traded at a new 52-week low today of $2.01. This new low was reached on above average trading volume as 1.3 million shares traded hands, while the average 30-day volume is approximately 892,000 shares. Potential upside of 25.1% exists fo...

Shares of Qualigen Therapeutics Inc. (NASDAQ:QLGN) traded at a new 52-week low today of $1.93. This new low was reached on above average trading volume as 1.3 million shares traded hands, while the average 30-day volume is approximately 892,000 shares. Qualigen Therapeutics Inc is a biot...

iRhythm Technologies (IRTC) -30% after Novitas publishes updated reimbursement rates.Qualigen Therapeutics (QLGN) -18% after it pulls marketing application for COVID-19 test.Gulf Resources (GURE) -11% on correcting and replacing - Q4 & FY2020 financial result...

Qualigen Therapeutics (QLGN) has announced that it has withdrawn the emergency use authorization application submitted to the FDA for FastPack COVID-19 diagnostic test. In reaction, the shares have dropped ~16.5% in post-market trading.Since the market application was submitted...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

The following slide deck was published by Qualigen Therapeutics, Inc. in conjunction with this event. For further details see: Qualigen Therapeutics (QLGN) Investor Presentation - Slideshow

CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chai...

CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announced today that it has promoted long-time officer Shishir Sinha to the ...

CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chai...